Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Immunovia Ord Shs IMMVF

Healthcare Medical Devices Diagnostics & Research
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus,... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (GREY:IMMVF)

Immunovia Publishes Interim Report for January-March 2023

PR Newswire May 23, 2023

Immunovia, Inc. market access increases when achieving Clinical Laboratory Permits from Pennsylvania and Maryland Departments of Health making IMMray(TM) PanCan-d test available in 48 US states

PR Newswire May 23, 2022

Immunovia reiterates its road to reimbursement for the IMMray(TM) PanCan-d test

PR Newswire April 22, 2021

Immunovia's PanFAM-1 Prospective Study Gathers Over 3000 Familial Hereditary Pancreatic Cancer Risk Samples And Will Be Analysed In The Second Half Of 2021

PR Newswire February 15, 2021

Chief Executive Officer, Patrik Dahlen Buys Immunovia Warrants

PR Newswire January 19, 2021

Proteomic data derived from Immunovia's IMMray(TM)-platform allows differential diagnosis of difficult to distinguish autoimmune diseases

PR Newswire January 7, 2021

Nomination Committee appointed for the 2021 Annual General Meeting of Immunovia AB (Publ)

PR Newswire November 10, 2020

Immunovia Provides Complementary Details on the IMMray(TM) PanCan-d Verification Study

PR Newswire November 2, 2020

Immunovia to Host Webinar Introducing New CEO, Patrik Dahlen

PR Newswire October 28, 2020
View More News ››

Opinion & Analysis (GREY:IMMVF)

No current opinion is available.
View More Opinion ››

Bullboard Posts (GREY:IMMVF)

Be the first to post on this bullboard.

Cloud DX Inc.

Cloud DX Inc.

Cloud DX Inc. is a Canada-based remote patient monitoring company that is a Health Canada licensed, United States Food and ...
View More »